sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities
Clicks: 201
ID: 148352
2016
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
8.4
/100
28 views
28 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune response is of great interest to dermato-oncologists. In this report, we present a case of multiple metastatic melanomas in the lung successfully treated with nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks), but with severe liver dysfunction.
| Reference Key |
furudate2016casesequential
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Sadanori Furudate;Taku Fujimura;Yumi Kambayashi;Takanori Hidaka;Akira Hashimoto;Setsuya Aiba |
| Journal | multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015 |
| Year | 2016 |
| DOI |
10.1159/000450974
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.